Thread by @alexandrosM

I am reading the slide deck of the TOGETHER trial and have a few questions of those who know a bit more about this stuff than me.

I'll try to keep this thread as neutral as possible.

To read the deck, click the link below, and press the "slides" button. rethinkingclinicaltrials.org/news/august-6-…

The trial says (implies) that it's using "shared control patients". In the "recruitment over time" slide, it shows that the placebo group was recruited in both "stages". Does this mean placebo patients from either stage were used to form control groups for each drug tested?

It also says (last bullet) that this is a "planned interim analysis of the fluvoxamine arm with the data cut from August 2nd, 2021". Does this mean the trial isn't done? What's the rationale for sharing data on other drugs if this was supposed to be about fluvoxamine?

I'm also confused about point 2 in the inclusion criteria. It says the patient has to present at an outpatient setting with acute clinical condition, symptoms beginning within 7 days of the screening.
1. What is the screening?

2. This seems to involve 3 dates: "screening, symptoms begin, presenting to outpatient". It tells us the gap between the first and second can be upto 7, but what about the third?
3. What is meant by "acute clinical condition"?

Am I reading this correctly that there were two IVM trials, one "low dose" and one "high dose"? If so, any explanation for why is it describing only one in the slides? Also, any explanation for why the fluvoxamine trial is longer?

In the ivermectin slide, there is this analysis, calculating Pr(Superiority), which comes out as 76% in favor of ivermectin. What kind of analysis is this? What is the appropriate way to understand these findings?